201 related articles for article (PubMed ID: 32218280)
1. Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer.
García P; Rosa L; Vargas S; Weber H; Espinoza JA; Suárez F; Romero-Calvo I; Elgueta N; Rivera V; Nervi B; Obreque J; Leal P; Viñuela E; Aguayo G; Muñiz S; Sagredo A; Roa JC; Bizama C
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218280
[TBL] [Abstract][Full Text] [Related]
2. Yes-associated protein 1 is required for proliferation and function of bovine granulosa cells in vitro†.
Plewes MR; Hou X; Zhang P; Liang A; Hua G; Wood JR; Cupp AS; Lv X; Wang C; Davis JS
Biol Reprod; 2019 Nov; 101(5):1001-1017. PubMed ID: 31350850
[TBL] [Abstract][Full Text] [Related]
3. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
[TBL] [Abstract][Full Text] [Related]
4. Wnt, RSPO and Hippo Signalling in the Intestine and Intestinal Stem Cells.
Kriz V; Korinek V
Genes (Basel); 2018 Jan; 9(1):. PubMed ID: 29316729
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic Hedgehog-Smoothened Signaling Depends on YAP1‒TAZ/TEAD Transcription to Restrain Differentiation in Basal Cell Carcinoma.
Yuan Y; Salinas Parra N; Chen Q; Iglesias-Bartolome R
J Invest Dermatol; 2022 Jan; 142(1):65-76.e7. PubMed ID: 34293352
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanism of Hippo-YAP1/TAZ Pathway in Heart Development, Disease, and Regeneration.
Chen X; Li Y; Luo J; Hou N
Front Physiol; 2020; 11():389. PubMed ID: 32390875
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of TAZ promotes cell proliferation, migration and epithelial-mesenchymal transition in ovarian cancer.
Chen G; Xie J; Huang P; Yang Z
Oncol Lett; 2016 Sep; 12(3):1821-1825. PubMed ID: 27588129
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic role of NF1 in gallbladder cancer through regulation of YAP1 stability by direct interaction with YAP1.
Zhang L; Jiang L; Zeng L; Jin Z; Dong X; Zhang Y; Chen L; Shu Y; Liu Y; Huang Y
J Transl Med; 2023 May; 21(1):306. PubMed ID: 37147639
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells.
Fisher ML; Grun D; Adhikary G; Xu W; Eckert RL
Oncotarget; 2017 Dec; 8(66):110257-110272. PubMed ID: 29299145
[TBL] [Abstract][Full Text] [Related]
10. The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.
Kandasamy S; Adhikary G; Rorke EA; Friedberg JS; Mickle MB; Alexander HR; Eckert RL
Mol Cancer Res; 2020 Mar; 18(3):343-351. PubMed ID: 31732616
[TBL] [Abstract][Full Text] [Related]
11. Verteporfin suppresses osteosarcoma progression by targeting the Hippo signaling pathway.
Yang X; Xu Y; Jiang C; Ma Z; Jin L
Oncol Lett; 2021 Oct; 22(4):724. PubMed ID: 34429764
[TBL] [Abstract][Full Text] [Related]
12. Mechanotransduction and Cytoskeleton Remodeling Shaping YAP1 in Gastric Tumorigenesis.
Zhang J; Zhou Y; Tang PMK; Cheng ASL; Yu J; To KF; Kang W
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30934860
[TBL] [Abstract][Full Text] [Related]
13. The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.
González-Alonso P; Zazo S; Martín-Aparicio E; Luque M; Chamizo C; Sanz-Álvarez M; Minguez P; Gómez-López G; Cristóbal I; Caramés C; García-Foncillas J; Eroles P; Lluch A; Arpí O; Rovira A; Albanell J; Piersma SR; Jimenez CR; Madoz-Gúrpide J; Rojo F
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365528
[TBL] [Abstract][Full Text] [Related]
14. Verteporfin induced SUMOylation of YAP1 in endometrial cancer.
Wang B; Shao W; Shi Y; Liao J; Chen X; Wang C
Am J Cancer Res; 2020; 10(4):1207-1217. PubMed ID: 32368396
[TBL] [Abstract][Full Text] [Related]
15. Expression of Hippo pathway genes and their clinical significance in colon adenocarcinoma.
Cho SY; Gwak JW; Shin YC; Moon D; Ahn J; Sol HW; Kim S; Kim G; Shin HM; Lee KH; Kim JY; Kim JS
Oncol Lett; 2018 Apr; 15(4):4926-4936. PubMed ID: 29541248
[TBL] [Abstract][Full Text] [Related]
16. YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer.
Kuser-Abali G; Alptekin A; Lewis M; Garraway IP; Cinar B
Nat Commun; 2015 Sep; 6():8126. PubMed ID: 28230103
[TBL] [Abstract][Full Text] [Related]
17. Targeting loss of the Hippo signaling pathway in
Sourbier C; Liao PJ; Ricketts CJ; Wei D; Yang Y; Baranes SM; Gibbs BK; Ohanjanian L; Spencer Krane L; Scroggins BT; Keith Killian J; Wei MH; Kijima T; Meltzer PS; Citrin DE; Neckers L; Vocke CD; Marston Linehan W
Oncotarget; 2018 Feb; 9(12):10723-10733. PubMed ID: 29535838
[TBL] [Abstract][Full Text] [Related]
18. Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer.
Yang P; Li Y; Hou J; Wu D; Zeng X; Zeng Z; Zhang J; Xiong Y; Chen L; Yang D; Wan X; Wu Z; Jia L; Liu Q; Lu Q; Zou X; Fang W; Zeng X; Zhou D
J Biol Chem; 2024 Apr; 300(6):107309. PubMed ID: 38657867
[TBL] [Abstract][Full Text] [Related]
19. Disruption of LTBP4 Inhibition-Induced TGFβ1 Activation Promoted Cell Proliferation and Metastasis in Skin Melanoma by Inhibiting the Activation of the Hippo-YAP1 Signaling Pathway.
Wang L; Tang D; Wu T; Sun F
Front Cell Dev Biol; 2021; 9():673904. PubMed ID: 35252214
[TBL] [Abstract][Full Text] [Related]
20. YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways.
Andrade D; Mehta M; Griffith J; Panneerselvam J; Srivastava A; Kim TD; Janknecht R; Herman T; Ramesh R; Munshi A
Oncotarget; 2017 Nov; 8(58):98495-98508. PubMed ID: 29228705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
